Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Strategies for managing refractoriness to platelet transfusions.

Maria E Dan1, Charles A Schiffer

  • 1Department of Pathology, Harper University Hospital, 3990 John R, Detroit, MI 48201, USA. MDan@dmc.org

Current Hematology Reports
|August 7, 2003
PubMed
Summary

Platelet transfusion refractoriness, a complication of intensive therapy, is often due to clinical factors treatable with aggressive management. Immune causes require HLA-matched platelets for successful patient support.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Leukemia·2025
Same author

Acute myeloid leukemia management and research in 2025.

CA: a cancer journal for clinicians·2024
Same author

Antifibrinolytics do not add to the benefits of platelet transfusion.

The Lancet. Haematology·2024
Same author

Project Confirm: Accelerated Drug Approvals for CML-Response.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Glasdigib fails to slay the hedgehog in pivotal AML trials.

Leukemia·2023
Same author

New patterns of genetic instability in chronic myeloid leukemia: interesting, but not ready for clinical use.

Haematologica·2023

Area of Science:

  • Hematology
  • Transfusion Medicine
  • Immunology

Background:

  • Platelet transfusions are crucial for intensive myelosuppressive therapy.
  • Chronic transfusion support can lead to refractoriness, defined by poor post-transfusion platelet count increments.
  • Refractoriness is commonly linked to clinical factors or immune-mediated destruction.

Purpose of the Study:

  • To review the causes and management of platelet transfusion refractoriness.
  • To highlight strategies for supporting patients with refractory platelet transfusions.

Main Methods:

  • Literature review of clinical factors contributing to refractoriness.
  • Analysis of immune-mediated platelet destruction mechanisms.
  • Evaluation of treatment strategies, including HLA-matched platelet transfusions.

Related Experiment Videos

Main Results:

  • Most cases of refractoriness are associated with treatable clinical factors.
  • Immune-mediated destruction, due to human leukocyte antigen (HLA) alloantibodies, affects a smaller patient group.
  • HLA-matched or cross-match compatible single-donor platelets are effective for immune-refractory patients.

Conclusions:

  • Aggressive management of clinical conditions can often overcome platelet transfusion refractoriness.
  • For immune-mediated refractoriness, HLA-matched platelet transfusions are the primary supportive strategy.
  • Effective management ensures continued support for patients undergoing intensive therapies.